A drug which could help advanced lung cancer sufferers has been approved for use on the NHS in Scotland.
Experts believe around 150 patients with a rare form of the cancer could benefit from pembrolizumab every year.
It is one of three medicines given the green light for routine use by the Scottish Medicines Consortium (SMC).
Patients with Crohn’s Disease and the aggressive blood cancer Hodgkin Lymphoma will also have access to drugs which have not previously been funded.
Pembrolizumab is used to treat advanced non-small cell lung cancer.
It can delay disease progression and may allow patients a better quality of life in the last months of their life, according to the SMC.
The decision to approve the drug was welcomed by Gregor McNie, of Cancer Research UK.
He said: “Scotland is the only part of the UK where lung cancer is the most common cancer. So it’s great news that …